Dizal to Present ZEGFROVY NSCLC Data at WCLC 2026
SHANGHAI, China, August 21, 2026 Dizal Pharmaceutical announced that emerging clinical data for ZEGFROVY® (sunvozertinib) will be presented at...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, China, August 21, 2026 Dizal Pharmaceutical announced that emerging clinical data for ZEGFROVY® (sunvozertinib) will be presented at...
NANJING, China, August 21, 2026 Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation (CDE) under...
San Francisco, California, August 20, 2026 Chai Discovery has announced a collaboration with Bristol Myers Squibb (BMS) to advance...
